Physician profile
David N Scheck
NPI 1689642902
$4,572.81
in general payments reported to CMS, 2019-2025
31 companies · $55.92 in 2025
The $55.92 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,164 · 2020: $347 · 2021: $279 · 2022: $393 · 2023: $321 · 2024: $14.16 · 2025: $55.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $365 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $364.99 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $2,171.44 | 2019 | |
| Abbvie INC. | $655.56 | 2020-2023 | Dalvance, Teflaro, Avycaz |
| Viiv Healthcare Company | $232.83 | 2019 | |
| Merck Sharp & Dohme LLC | $178.34 | 2019-2025 | Zerbaxa |
| Novartis Pharmaceuticals Corporation | $137.35 | 2019-2020 | |
| Seagen INC. | $117.91 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.46 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $100.17 | 2019-2021 | |
| Celgene Corporation | $95.49 | 2019 | |
| Glaxosmithkline, LLC. | $80.13 | 2022 | |
| Genentech USA, INC. | $75.11 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.04 | 2019 | |
| Lilly USA, LLC | $57.86 | 2019-2020 | |
| Janssen Biotech, INC. | $56.86 | 2019-2020 | |
| Blueprint Medicines Corporation | $41.99 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $41.03 | 2019 | |
| Genzyme Corporation | $35.75 | 2019 | |
| Array Biopharma INC | $32.98 | 2019 | |
| Astellas Pharma US INC | $32.51 | 2021 | |
| Eisai INC. | $30.52 | 2020 | |
| Paratek Pharmaceuticals, INC. | $30.21 | 2024-2025 | Nuzyra |
| Pharmacyclics LLC, An Abbvie Company | $30.07 | 2021 | |
| Kyowa Kirin, INC. | $29.80 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $26.63 | 2020 | |
| Taiho Oncology, INC. | $22.39 | 2021 | |
| Amag Pharmaceuticals, INC. | $19.91 | 2019 | |
| Amgen INC. | $16.69 | 2021 | |
| Clovis Oncology, INC. | $15.86 | 2021 | |
| Karyopharm Therapeutics INC. | $14.84 | 2021 | |
| Puma Biotechnology, INC. | $12.28 | 2019 | |
| Epizyme, INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Scheck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.